{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:41Z","timestamp":1789434161904,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04727-1","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:44:51Z","timestamp":1782560691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS\u2011CoV\u20112"],"prefix":"10.1186","volume":"24","author":[{"given":"Ahmed","family":"Elkashif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralimanohara S. T.","family":"Murala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Alhashimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gairola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Pires","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Boley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekramy E.","family":"Sayedahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourapura J.","family":"Renukaradhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"6","key":"4727_CR1","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/evolut\/qpae041","volume":"78","author":"SP Otto","year":"2024","unstructured":"Otto SP, MacPherson A, Colijn C. Endemic does not mean constant as SARS-CoV-2 continues to evolve. Evolution. 2024;78(6):1092\u2013108.","journal-title":"Evolution"},{"issue":"7862","key":"4727_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/d41586-021-01505-x","volume":"594","author":"H Ledford","year":"2021","unstructured":"Ledford H. Six months of COVID vaccines: what 1.7 billion doses have taught scientists. Nature. 2021;594(7862):164\u20137.","journal-title":"Nature"},{"issue":"6","key":"4727_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov PV, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21(6):361\u201379.","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"4727_CR4","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale F, et al. Evaluation of waning of SARS-CoV-2 vaccine\u2013induced immunity: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(5):e2310650\u20132310650.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"4727_CR5","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku Y, et al. Virological characteristics of the SARS-CoV-2 KP. 3, LB. 1, and KP. 2.3 variants. Lancet Infect Dis. 2024;24(8):e482\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"4727_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41559-023-02082-0","volume":"7","author":"SV Kuchipudi","year":"2023","unstructured":"Kuchipudi SV, et al. Coordinated surveillance is essential to monitor and mitigate the evolutionary impacts of SARS-CoV-2 spillover and circulation in animal hosts. Nat Ecol Evol. 2023;7(7):956\u20139.","journal-title":"Nat Ecol Evol"},{"issue":"1","key":"4727_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","volume":"29","author":"SM Scheaffer","year":"2023","unstructured":"Scheaffer SM, et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA. 5 Omicron variant in mice. Nat Med. 2023;29(1):247\u201357.","journal-title":"Nat Med"},{"issue":"4","key":"4727_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41579-023-01003-z","volume":"22","author":"S Steiner","year":"2024","unstructured":"Steiner S, et al. SARS-CoV-2 biology and host interactions. Nat Rev Microbiol. 2024;22(4):206\u201325.","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"4727_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"2","key":"4727_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202\u201321.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"4727_CR11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/vaccines10111807","volume":"10","author":"J Li","year":"2022","unstructured":"Li J, et al. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines. 2022;10(11):1807.","journal-title":"Vaccines"},{"issue":"5","key":"4727_CR12","doi-asserted-by":"publisher","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","volume":"42","author":"P Qu","year":"2023","unstructured":"Qu P, et al. Enhanced evasion of neutralizing antibody response by Omicron XBB. 1.5, CH. 1.1, and CA. 3.1 variants. Cell Rep. 2023;42(5):112443.","journal-title":"Cell Rep"},{"issue":"1","key":"4727_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41541-025-01198-7","volume":"10","author":"M Alhashimi","year":"2025","unstructured":"Alhashimi M, et al. A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants. npj Vaccines. 2025;10(1):159.","journal-title":"npj Vaccines"},{"key":"4727_CR14","doi-asserted-by":"publisher","first-page":"1450114","DOI":"10.3389\/fimmu.2024.1450114","volume":"15","author":"Y Tang","year":"2024","unstructured":"Tang Y, et al. M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication. Front Immunol. 2024;15:1450114. https:\/\/doi.org\/10.3389\/fimmu.2024.1450114","journal-title":"Front Immunol"},{"issue":"6","key":"4727_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/v13061115","volume":"13","author":"Z Bai","year":"2021","unstructured":"Bai Z, et al. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses. 2021;13(6):1115.","journal-title":"Viruses"},{"issue":"10","key":"4727_CR16","doi-asserted-by":"publisher","first-page":"109664","DOI":"10.1016\/j.celrep.2021.109664","volume":"36","author":"T Dangi","year":"2021","unstructured":"Dangi T, et al. Combining spike-and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep. 2021;36(10):109664.","journal-title":"Cell Rep"},{"key":"4727_CR17","doi-asserted-by":"publisher","first-page":"679841","DOI":"10.3389\/fimmu.2021.679841","volume":"12","author":"P J\u00f6rri\u00dfen","year":"2021","unstructured":"J\u00f6rri\u00dfen P, et al. Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol. 2021;12:679841. https:\/\/doi.org\/10.3389\/fimmu.2021.679841","journal-title":"Front Immunol"},{"issue":"662","key":"4727_CR18","doi-asserted-by":"publisher","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","volume":"14","author":"RL Hajnik","year":"2022","unstructured":"Hajnik RL, et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci Transl Med. 2022;14(662):eabq1945.","journal-title":"Sci Transl Med"},{"issue":"25","key":"4727_CR19","first-page":"2905","volume":"136","author":"MD Keller","year":"2020","unstructured":"Keller MD, et al. SARS-CoV-2\u2013specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood J Am Soc Hematol. 2020;136(25):2905\u201317.","journal-title":"Blood J Am Soc Hematol"},{"issue":"10","key":"4727_CR20","doi-asserted-by":"publisher","first-page":"e1345","DOI":"10.1002\/cti2.1345","volume":"10","author":"A Elkashif","year":"2021","unstructured":"Elkashif A, et al. Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Clin Translational Immunol. 2021;10(10):e1345.","journal-title":"Clin Translational Immunol"},{"issue":"2","key":"4727_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","volume":"22","author":"A Singanayagam","year":"2022","unstructured":"Singanayagam A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"4727_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/v13081493","volume":"13","author":"M Alhashimi","year":"2021","unstructured":"Alhashimi M, et al. Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases. Viruses. 2021;13(8):1493.","journal-title":"Viruses"},{"issue":"5","key":"4727_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/gt.2010.1","volume":"17","author":"A Sharma","year":"2010","unstructured":"Sharma A, et al. Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther. 2010;17(5):634\u201342.","journal-title":"Gene Ther"},{"issue":"1","key":"4727_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.virusres.2011.09.031","volume":"163","author":"M Tandon","year":"2012","unstructured":"Tandon M, et al. Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res. 2012;163(1):202\u201311.","journal-title":"Virus Res"},{"key":"4727_CR25","doi-asserted-by":"publisher","unstructured":"Mittal SK, Ahi YS, Vemula SV. Xenogenic adenoviral vectors. Adenoviral Vectors for Gene Therapy. Academic Press; 2016:495\u2013528. https:\/\/doi.org\/10.1016\/B978-0-12-800276-6.00019-X.","DOI":"10.1016\/B978-0-12-800276-6.00019-X"},{"issue":"12","key":"4727_CR26","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/v14122727","volume":"14","author":"WC Wang","year":"2022","unstructured":"Wang WC, Sayedahmed EE, Mittal SK. Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy. Viruses. 2022;14(12):2727. https:\/\/doi.org\/10.3390\/v14122727.","journal-title":"Viruses"},{"issue":"8","key":"4727_CR27","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.xcrm.2021.100372","volume":"2","author":"A Khan","year":"2021","unstructured":"Khan A, et al. A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. Cell Rep Med. 2021;2(8):100372.","journal-title":"Cell Rep Med"},{"issue":"4","key":"4727_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.ymthe.2023.02.012","volume":"31","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, et al. Protein expression\/secretion boost by a novel unique 21-mer\u2009<\u2009em>cis-regulatory motif (Exin21) via mRNA stabilization. Mol Ther. 2023;31(4):1136\u201358.","journal-title":"Mol Ther"},{"issue":"3","key":"4727_CR29","doi-asserted-by":"publisher","first-page":"102594","DOI":"10.1016\/j.omtn.2025.102594","volume":"36","author":"W-C Wang","year":"2025","unstructured":"Wang W-C, et al. A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets. Mol Therapy Nucleic Acids. 2025;36(3):102594. https:\/\/doi.org\/10.1016\/j.omtn.2025.102594.","journal-title":"Mol Therapy Nucleic Acids"},{"issue":"12","key":"4727_CR30","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1128\/JVI.76.12.5882-5892.2002","volume":"76","author":"AL van Olphen","year":"2002","unstructured":"van Olphen AL, Mittal SK. Development and characterization of bovine\u00d7 human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J Virol. 2002;76(12):5882\u201392.","journal-title":"J Virol"},{"issue":"1","key":"4727_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham FL, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36(1):59\u201372.","journal-title":"J Gen Virol"},{"issue":"6","key":"4727_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/BF02369439","volume":"22","author":"L Chen","year":"1996","unstructured":"Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet. 1996;22(6):477\u201388.","journal-title":"Somat Cell Mol Genet"},{"issue":"D1","key":"4727_CR33","doi-asserted-by":"publisher","first-page":"D436","DOI":"10.1093\/nar\/gkae1092","volume":"53","author":"R Vita","year":"2025","unstructured":"Vita R, et al. The Immune Epitope Database (IEDB): 2024 update. Nucleic Acids Res. 2025;53(D1):D436\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4727_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2008.12","volume":"16","author":"N Singh","year":"2008","unstructured":"Singh N, et al. Bovine adenoviral vector\u2013based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther. 2008;16(5):965\u201371.","journal-title":"Mol Ther"},{"issue":"3","key":"4727_CR35","doi-asserted-by":"publisher","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","volume":"7","author":"A Pandey","year":"2012","unstructured":"Pandey A, et al. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS ONE. 2012;7(3):e33428.","journal-title":"PLoS ONE"},{"issue":"11","key":"4727_CR36","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1099\/0022-1317-78-11-2933","volume":"78","author":"Z Papp","year":"1997","unstructured":"Papp Z, et al. Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. J Gen Virol. 1997;78(11):2933\u201343.","journal-title":"J Gen Virol"},{"issue":"9509","key":"4727_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","volume":"367","author":"MA Hoelscher","year":"2006","unstructured":"Hoelscher MA, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet. 2006;367(9509):475\u201381.","journal-title":"Lancet"},{"key":"4727_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.omtm.2023.06.009","volume":"30","author":"EE Sayedahmed","year":"2023","unstructured":"Sayedahmed EE, et al. Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine. Mol Therapy Methods Clin Dev. 2023;30:194\u2013207.","journal-title":"Mol Therapy Methods Clin Dev"},{"issue":"45","key":"4727_CR39","doi-asserted-by":"publisher","first-page":"27158","DOI":"10.1074\/jbc.M115.682708","volume":"290","author":"SK Mittal","year":"2015","unstructured":"Mittal SK, et al. Interleukin 10 (IL-10)-mediated immunosuppression: March-I induction regulates antigen presentation by macrophages but not dendritic cells. J Biol Chem. 2015;290(45):27158\u201367.","journal-title":"J Biol Chem"},{"issue":"10","key":"4727_CR40","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1128\/jvi.70.10.7103-7107.1996","volume":"70","author":"DP Sharma","year":"1996","unstructured":"Sharma DP, et al. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol. 1996;70(10):7103\u20137.","journal-title":"J Virol"},{"issue":"7","key":"4727_CR41","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20092532","volume":"207","author":"PA Darrah","year":"2010","unstructured":"Darrah PA, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med. 2010;207(7):1421\u201333.","journal-title":"J Exp Med"},{"key":"4727_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/82_2010_96","volume":"350","author":"EB Wilson","year":"2011","unstructured":"Wilson EB, Brooks DG. The role of IL-10 in regulating immunity to persistent viral infections. Negat Co-Receptors Ligands. 2011; 350:39-65.","journal-title":"Negat Co-Receptors Ligands"},{"issue":"3","key":"4727_CR43","doi-asserted-by":"publisher","first-page":"e2183","DOI":"10.1002\/rmv.2183","volume":"31","author":"A Arashkia","year":"2021","unstructured":"Arashkia A, et al. Severe acute respiratory syndrome-coronavirus\u20102 spike (S) protein based vaccine candidates: State of the art and future prospects. Rev Med Virol. 2021;31(3):e2183.","journal-title":"Rev Med Virol"},{"key":"4727_CR44","doi-asserted-by":"publisher","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","volume":"12","author":"D Martinez-Flores","year":"2021","unstructured":"Martinez-Flores D, et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol. 2021;12:701501.","journal-title":"Front Immunol"},{"issue":"4","key":"4727_CR45","doi-asserted-by":"publisher","first-page":"msad085","DOI":"10.1093\/molbev\/msad085","volume":"40","author":"JD Bloom","year":"2023","unstructured":"Bloom JD, et al. Evolution of the SARS-CoV-2 mutational spectrum. Mol Biol Evol. 2023;40(4):msad085.","journal-title":"Mol Biol Evol"},{"issue":"11","key":"4727_CR46","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41564-023-01504-w","volume":"8","author":"C Roemer","year":"2023","unstructured":"Roemer C, et al. SARS-CoV-2 evolution in the Omicron era. Nat Microbiol. 2023;8(11):1952\u20139.","journal-title":"Nat Microbiol"},{"issue":"4","key":"4727_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/vaccines13040406","volume":"13","author":"MS Murala","year":"2025","unstructured":"Murala MS, et al. Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2. Vaccines. 2025;13(4):406.","journal-title":"Vaccines"},{"issue":"1","key":"4727_CR48","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1473-3099(22)00640-5","volume":"23","author":"DS Hui","year":"2023","unstructured":"Hui DS. Hybrid immunity and strategies for COVID-19 vaccination. Lancet Infect Dis. 2023;23(1):2\u20133.","journal-title":"Lancet Infect Dis"},{"key":"4727_CR49","doi-asserted-by":"publisher","unstructured":"Tzenios N, Chahine M, Tazanios M. Better strategies for coronavirus (COVID-19) vaccination. Special J Med Acad other Life Sci. 2023. 1(2). https:\/\/doi.org\/10.58676\/sjmas.v1i2.11.","DOI":"10.58676\/sjmas.v1i2.11"},{"key":"4727_CR50","doi-asserted-by":"publisher","first-page":"117793222110258","DOI":"10.1177\/11779322211025876","volume":"15","author":"R Gorkhali","year":"2021","unstructured":"Gorkhali R, et al. Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform Biol insights. 2021;15:11779322211025876.","journal-title":"Bioinform Biol insights"},{"issue":"4","key":"4727_CR51","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1182\/blood-2003-12-4302","volume":"104","author":"S Bhattacharyya","year":"2004","unstructured":"Bhattacharyya S, et al. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K\/Akt pathway and of I\u03baB kinase activity. Blood. 2004;104(4):1100\u20139.","journal-title":"Blood"},{"key":"4727_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fimmu.2018.00455","volume":"9","author":"S Sch\u00fclke","year":"2018","unstructured":"Sch\u00fclke S. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front Immunol. 2018;9:455.","journal-title":"Front Immunol"},{"issue":"39\u201340","key":"4727_CR53","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1016\/j.vaccine.2007.07.035","volume":"25","author":"S Roy","year":"2007","unstructured":"Roy S, et al. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007;25(39\u201340):6845\u201351.","journal-title":"Vaccine"},{"issue":"43","key":"4727_CR54","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1016\/j.vaccine.2014.08.049","volume":"32","author":"A Sharma","year":"2014","unstructured":"Sharma A, et al. Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection. Vaccine. 2014;32(43):5761\u20138.","journal-title":"Vaccine"},{"issue":"2","key":"4727_CR55","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1073\/pnas.1407466112","volume":"112","author":"DG Carnathan","year":"2015","unstructured":"Carnathan DG, et al. Activated CD4\u2009+\u2009CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag\/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci. 2015;112(2):518\u201323.","journal-title":"Proc Natl Acad Sci"},{"key":"4727_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","volume":"21","author":"HC Ertl","year":"2016","unstructured":"Ertl HC. Viral vectors as vaccine carriers. Curr Opin Virol. 2016;21:1\u20138.","journal-title":"Curr Opin Virol"},{"key":"4727_CR57","doi-asserted-by":"publisher","unstructured":"Xu K, et al. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M\/E Protects against Zika Virus Infection and Testis Damage. J Virol. 2018;92(6). https:\/\/doi.org\/10.1128\/jvi.01722-17.","DOI":"10.1128\/jvi.01722-17"},{"issue":"4","key":"4727_CR58","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/vaccines8040574","volume":"8","author":"EE Sayedahmed","year":"2020","unstructured":"Sayedahmed EE, et al. Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines. Vaccines. 2020;8(4):574.","journal-title":"Vaccines"},{"issue":"5","key":"4727_CR59","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/vaccines13050494","volume":"13","author":"EE Sayedahmed","year":"2025","unstructured":"Sayedahmed EE, et al. Bovine Adenoviral Vector-Based Platform for Vaccine Development. Vaccines. 2025;13(5):494.","journal-title":"Vaccines"},{"issue":"2","key":"4727_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/vaccines12020157","volume":"12","author":"EE Sayedahmed","year":"2024","unstructured":"Sayedahmed EE, et al. Development of NP-Based universal vaccine for Influenza A Viruses. Vaccines. 2024;12(2):157.","journal-title":"Vaccines"},{"key":"4727_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbi.2021.12.007","volume":"100","author":"MG Frank","year":"2022","unstructured":"Frank MG, et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav Immun. 2022;100:267\u201377.","journal-title":"Brain Behav Immun"},{"issue":"7830","key":"4727_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","volume":"586","author":"NB Mercado","year":"2020","unstructured":"Mercado NB, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583\u20138.","journal-title":"Nature"},{"issue":"1","key":"4727_CR63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, et al. A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020;183(1):169\u2013e18413.","journal-title":"Cell"},{"issue":"1","key":"4727_CR64","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jinf.2020.04.002","volume":"81","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6\u201312.","journal-title":"J Infect"},{"issue":"6","key":"4727_CR65","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes BJ et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. https:\/\/doi.org\/10.1084\/jem.20200652.","journal-title":"J Exp Med"},{"issue":"7","key":"4727_CR66","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/JVI.02192-06","volume":"81","author":"J Zhu","year":"2007","unstructured":"Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol. 2007;81(7):3170\u201380.","journal-title":"J Virol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04727-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04727-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04727-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:03:37Z","timestamp":1789430617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04727-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4727"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04727-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"871"}}